DiaMetra are pleased to announce the release of the improved Androstenedione ELISA which is now calibrated against a recognised standard reference method.
The DiaMetra Androstenedione ELISA measures a patient’s Androstenedione level, offering clinicians access to an additional assay to support investigations into androgen disorders such as hyperandrogenism, congenital adrenal hyperplasia (CAH), polycystic ovarian syndrome (PCOS) or adrenal insufficiency. Increased androstenedione levels are observed in CAH and PCOS whereas individuals with adrenal insufficiency or ovarian failure display suppressed levels.
Androstenedione is synthesised from 17-OH progesterone and dehydroepiandrosterone (DHEA), occurring in both the adrenal glands and gonads under the influence of adrenocorticotrophic hormone (ACTH) or gonadotrophins respectively. It serves as a precursor compound in the synthesis of oestrogen and testosterone.
Measurement of androstenedione is commonly used to determine the cause of symptoms of androgen excess, which is characterised by an excess of specific hormones such as testosterone and DHEA-S.
The improved Androstenedione ELISA is a sensitive method which provides benefits such as its alignment to the JCTLM ID LC-MS/MS method, detailed reference ranges in children and adults a short time to first result.